Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : ALNY exchanges : Nasdaq save search
Alnylam to Webcast Investor Event to Discuss Results from KARDIA-2 Phase 2 Study of Zilebesiran at American College of Cardiology Scientific Session
Published: 2024-03-20 (Crawled : 13:00) - biospace.com/
ALNY | $146.86 -0.57% -0.57% 350K
|
Health Technology
|
| O: -0.11%
H: 0.43%
C: -0.01%
cardiology results study
Rapport Therapeutics Appoints Pioneering Industry Leader John Maraganore to Board of Directors
Published: 2024-03-19 (Crawled : 15:00) - biospace.com/
ALNY | $146.86 -0.57% -0.57% 350K
|
Health Technology
|
| O: -0.33%
H: 1.88%
C: 0.84%
therapeutics
Zenas BioPharma Appoints Patricia Allen to its Board of Directors
Published: 2024-03-06 (Crawled : 16:00) - biospace.com/
ALNY | $146.86 -0.57% -0.57% 350K
|
Health Technology
|
| O: 0.31%
H: 0.06%
C: -0.33%
biopharma
Alnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran is Added to Standard of Care Antihypertensives
Published: 2024-03-05 (Crawled : 16:00) - biospace.com/
SNY | $45.81 -0.93% -0.94% 1.4M
|
Health Technology
|
| O: 1.17%
H: 0.0%
C: 0.0%
ALNY | $146.86 -0.57% -0.57% 350K
|
Health Technology
|
| O: -0.73%
H: 1.52%
C: 0.5%
positive blood care topline results study
Vir Biotechnology Completes Enrollment of Phase 2 Chronic Hepatitis Delta SOLSTICE Trial Ahead of Schedule
Published: 2024-03-05 (Crawled : 15:30) - biospace.com/
VIR | $8.36 -2.45% -2.51% 660K
|
Health Technology
|
| O: -0.09%
H: 2.06%
C: -2.68%
ALNY | $146.86 -0.57% -0.57% 350K
|
Health Technology
|
| O: -0.73%
H: 1.52%
C: 0.5%
hepatitis trial
Alnylam to Webcast Presentations at Upcoming March Investor Conferences - February 27, 2024
Published: 2024-02-27 (Crawled : 14:00) - biospace.com/
ALNY | $146.86 -0.57% -0.57% 350K
|
Health Technology
|
| O: 0.84%
H: 0.82%
C: -0.63%
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
Published: 2024-02-22 (Crawled : 00:00) - biospace.com/
XNCR | $18.94 -5.82% -6.18% 500K
|
Health Technology
|
| O: -0.87%
H: 2.89%
C: 2.14%
VIR | $8.36 -2.45% -2.51% 660K
|
Health Technology
|
| O: -0.69%
H: 2.99%
C: 2.59%
ALNY | $146.86 -0.57% -0.57% 350K
|
Health Technology
|
| O: -0.17%
H: 6.18%
C: 5.4%
year update financial results
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Period Activity
Published: 2024-02-15 (Crawled : 14:30) - biospace.com/
SNYNF | $92.966 -2.18% 630
|
Health Technology
|
| O: 1.16%
H: 1.48%
C: 0.89%
SNY | $45.81 -0.93% -0.94% 1.4M
|
Health Technology
|
| O: 1.86%
H: 0.0%
C: 0.0%
ALNY | $146.86 -0.57% -0.57% 350K
|
Health Technology
|
| O: -8.62%
H: 2.18%
C: -1.71%
year pharmaceuticals financial results
Liver Disease Therapeutics Competitive Landscape and Market Forecasts to 2028
Published: 2024-02-12 (Crawled : 20:00) - prnewswire.com
ALPMY | $9.2715 -1.11% 500K
|
Manufacturing
|
| O: 0.37%
H: 0.74%
C: 0.28%
BMY | $48.26 -0.52% 0.04% 12M
|
Health Technology
|
| O: -0.18%
H: 0.48%
C: -1.91%
ABBV | $162.54 0.54% 0.0% 4.8M
|
Health Technology
|
| O: 0.8%
H: 0.0%
C: 0.0%
SNY | $45.81 -0.93% -0.94% 1.4M
|
Health Technology
|
| O: -0.06%
H: 0.0%
C: 0.0%
GILD | $67.32 -0.64% -0.64% 5M
|
Health Technology
|
| O: 0.32%
H: 0.11%
C: -1.55%
ALNY | $146.86 -0.57% -0.57% 350K
|
Health Technology
|
| O: -2.63%
H: 0.98%
C: -1.75%
liver disease therapeutics market
Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
Published: 2024-02-02 (Crawled : 12:00) - globenewswire.com
TSVT | $4.87 -2.31% -2.36% 930K
|
|
| O: -1.16%
H: 9.94%
C: 2.34%
SNY | $45.81 -0.93% -0.94% 1.4M
|
Health Technology
|
| O: -0.93%
H: 0.0%
C: 0.0%
REGN | $894.265 -0.48% -0.48% 610K
|
Health Technology
|
| O: 1.4%
H: 0.28%
C: -2.68%
ALNY | $146.86 -0.57% -0.57% 350K
|
Health Technology
|
| O: -1.23%
H: 1.0%
C: 0.17%
year financial results
Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2023 Financial Results
Published: 2024-01-29 (Crawled : 14:30) - biospace.com/
ALNY | $146.86 -0.57% -0.57% 350K
|
Health Technology
|
| O: -0.27%
H: 1.32%
C: 1.02%
conference year financial results
Non-Alcoholic Fatty Liver Disease Market to Observe Impressive Growth by 2032, Evaluates DelveInsight | Key Companies - MediciNova, Eli Lilly and Company, AstraZeneca, Madrigal Pharmaceuticals, BioMarin Pharmaceutical, GlaxoSmithKline, Pfizer
Published: 2024-01-22 (Crawled : 22:00) - prnewswire.com
LLY | $746.74 -0.54% 1.01% 2.5M
|
Health Technology
|
| O: -0.51%
H: 0.37%
C: 0.32%
MDGL M | $233.15 0.77% 0.76% 340K
|
Health Technology
|
| O: 1.29%
H: 0.35%
C: -3.04%
HEPA | $2.04 -6.42% -6.86% 26K
|
Health Technology
|
| O: -0.48%
H: 7.69%
C: 1.44%
ALT | $7.54 -0.13% -0.13% 2.7M
|
Commercial Services
|
| O: -0.8%
H: 6.02%
C: 0.6%
ALNY | $146.86 -0.57% -0.57% 350K
|
Health Technology
|
| O: 0.46%
H: 3.04%
C: 2.67%
ETNB | $9.37 -1.26% -1.28% 550K
|
Health Technology
|
| O: 1.19%
H: 0.63%
C: -0.72%
liver disease companies key growth market
Opinion: Brain Health Matters; We Must Not Lose Momentum
Published: 2024-01-08 (Crawled : 07:00) - biospace.com/
ALNY | $146.86 -0.57% -0.57% 350K
|
Health Technology
|
| O: -0.05%
H: 4.12%
C: 3.98%
health momentum
Alnylam to Webcast Presentation at 42nd Annual J.P. Morgan Healthcare Conference
Published: 2024-01-02 (Crawled : 13:30) - biospace.com/
ALNY | $146.86 -0.57% -0.57% 350K
|
Health Technology
|
| O: -0.8%
H: 3.23%
C: 2.66%
conference presentation
Alnylam Highlights Significant Progress with Platform Innovation and Clinical Pipeline at R&D Day
Published: 2023-12-13 (Crawled : 14:30) - biospace.com/
SNYNF | $92.966 -2.18% 630
|
Health Technology
|
| O: -0.06%
H: 2.36%
C: 2.36%
SNY | $45.81 -0.93% -0.94% 1.4M
|
Health Technology
|
| O: -0.27%
H: 2.28%
C: 2.16%
ALNY | $146.86 -0.57% -0.57% 350K
|
Health Technology
|
| O: -0.14%
H: 4.22%
C: 3.97%
day innovation pipeline platform
Alnylam to Webcast Virtual R&D Day - December 6, 2023
Published: 2023-12-06 (Crawled : 14:30) - biospace.com/
ALNY | $146.86 -0.57% -0.57% 350K
|
Health Technology
|
| O: 0.37%
H: 3.09%
C: 2.35%
day
Alnylam Ranks #1 on Boston Globe’s Top Places to Work List for 2023
Published: 2023-11-30 (Crawled : 15:30) - biospace.com/
ALNY | $146.86 -0.57% -0.57% 350K
|
Health Technology
|
| O: 0.93%
H: 2.49%
C: 1.64%
work
Vir Biotechnology to Present New Data from Its Ongoing Phase 2 Chronic Hepatitis Delta and B Trials Today at AASLD’s The Liver Meeting® 2023
Published: 2023-11-13 (Crawled : 14:30) - biospace.com/
VIR | $8.36 -2.45% -2.51% 660K
|
Health Technology
|
| O: 1.02%
H: 4.5%
C: 3.38%
ALNY | $146.86 -0.57% -0.57% 350K
|
Health Technology
|
| O: 0.04%
H: 1.92%
C: 1.89%
meeting hepatitis liver ongoing trials today
Vir Biotechnology to Present Late-Breaking Data from Its Ongoing Phase 2 Chronic Hepatitis B and Delta Trials at AASLD’s The Liver Meeting® 2023
Published: 2023-11-10 (Crawled : 15:00) - biospace.com/
VIR | $8.36 -2.45% -2.51% 660K
|
Health Technology
|
| O: 0.98%
H: 7.06%
C: 6.93%
ALNY | $146.86 -0.57% -0.57% 350K
|
Health Technology
|
| O: 0.49%
H: 0.74%
C: -2.08%
meeting hepatitis liver ongoing trials
Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2023
Published: 2023-11-07 (Crawled : 15:00) - biospace.com/
ABBV | $162.54 0.54% 0.0% 4.8M
|
Health Technology
|
| O: -0.28%
H: 0.0%
C: 0.0%
SMMT | $3.53 -3.42% -3.54% 1.3M
|
Health Technology
|
| O: -0.46%
H: 6.68%
C: -11.75%
PLSE | $7.75 -0.9% -0.9% 110K
|
Health Technology
|
| O: 0.39%
H: 6.43%
C: 1.92%
BIIB | $195.16 -0.83% -0.85% 870K
|
Health Technology
|
| O: -0.82%
H: 0.73%
C: -0.4%
ALNY | $146.86 -0.57% -0.57% 350K
|
Health Technology
|
| O: 1.06%
H: 2.42%
C: 0.76%
therapeutics financial results
Gainers vs Losers
| 58% | 42% |
Top 10 Gainers
WISA 4 | $6.06 246.29% 71.12% 200M
|
Electronic Technology
VIAO | $0.265 -13.96% 35.85% 960K
|
Electronic Technology
JAGX | $0.178 49.83% 33.26% 600M
|
Health Technology
SXTC | $1.68 43.59% 30.36% 34M
|
Health Technology
DYNT | $0.531 43.36% 30.24% 22M
|
Health Technology
KA | $0.4796 41.06% 29.11% 5.3M
|
Manufacturing
PALI | $5.86 40.87% 29.01% 29M
|
Manufacturing
CLNN | $0.319 -3.74% 28.75% 6.3M
|
BSGM | $1.52 38.18% 27.63% 3.3M
|
Health Technology
MCBC | $13.67 37.66% 27.36% 2.2M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.